{
    "id": "3485f152-22bd-e5bd-e063-6394a90afa5b",
    "indications": "progesterone capsules indicated prevention endometrial hyperplasia nonhysterectomized postmenopausal women receiving conjugated estrogens tablets . also indicated secondary amenorrhea .",
    "contraindications": "prevention endometrial hyperplasia progesterone capsules given single daily dose bedtime , 200 mg orally 12 days sequentially per 28-day cycle , postmenopausal women uterus receiving daily conjugated estrogens tablets . treatment secondary amenorrhea progesterone capsules may given single daily dose 400 mg bedtime 10 days . women may experience difficulty swallowing progesterone capsules . women , progesterone capsules taken glass water standing position .",
    "warningsAndPrecautions": "progesterone , capsules 100 mg available oval yellow , opaque , capsule imprinted p-3 black ink . ndc 76420-582-30 ( bottle 30 ) ( repackaged ndc 69452-233-20 ) ndc 76420-582-60 ( bottle 60 ) ( repackaged ndc 69452-233-20 ) ndc 76420-582-90 ( bottle 90 ) ( repackaged ndc 69452-233-20 ) ndc 76420-582-10 ( bottle 100 ) ( relabeled/repackaged ndc 69452-233-20 ) progesterone , capsules 200 mg available oval white , opaque , capsule imprinted p-4 black ink . ndc 76420-580-30 ( bottle 30 ) ( repackaged ndc 69452-234-20 ) ndc 76420-580-60 ( bottle 60 ) ( repackaged ndc 69452-234-20 ) ndc 76420-580-90 ( bottle 90 ) ( repackaged ndc 69452-234-20 ) ndc 76420-580-10 ( bottle 100 ) ( relabeled ndc 69452-234-20 ) store 20-25째c ( 68-77째f ) . [ usp controlled room temperature ] protect excessive moisture keep reach children . dispense tight , light-resistant container defined usp/nf , accompanied patient insert . relabeled repackaged : enovachem pharmaceuticals torrance , ca 90501",
    "adverseReactions": "progesterone capsules used women following conditions : progesterone capsules used patients known hypersensitivity ingredients . progesterone capsules contain peanut oil never used patients allergic peanuts . undiagnosed abnormal genital bleeding . known , suspected , history breast cancer . active deep vein thrombosis , pulmonary embolism history conditions . active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions . known liver dysfunction disease . known suspected pregnancy .",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "PEANUT OIL",
            "code": "5TL50QU0W4"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "PROGESTERONE",
            "code": "4G7DS2Q64Y"
        }
    ],
    "organization": "Asclemed USA, Inc.",
    "name": "PROGESTERONE",
    "effectiveTime": "20250507",
    "indications_original": "Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.",
    "contraindications_original": "Prevention of Endometrial Hyperplasia\n                  Progesterone capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to postmenopausal women with a uterus who are receiving daily conjugated estrogens tablets.\n                  Treatment of Secondary Amenorrhea\n                  Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days.\n                  Some women may experience difficulty swallowing progesterone capsules. For these women, progesterone capsules should be taken with a glass of water while in the standing position.",
    "warningsAndPrecautions_original": "Progesterone, capsules 100 mg are available as an oval yellow, opaque, capsule imprinted with P-3 in black ink.\n                  NDC 76420-582-30 (Bottle of 30) (repackaged from NDC 69452-233-20) \n                  NDC 76420-582-60 (Bottle of 60) (repackaged from NDC 69452-233-20)\n                  NDC 76420-582-90 (Bottle of 90) (repackaged from NDC 69452-233-20)\n                  NDC 76420-582-10 (Bottle of 100) (relabeled/repackaged from NDC 69452-233-20)\n                  Progesterone, capsules 200 mg are available as an oval white, opaque, capsule imprinted with P-4 in black ink.\n                  NDC 76420-580-30 (Bottle of 30) (repackaged from NDC 69452-234-20)\n                  NDC 76420-580-60 (Bottle of 60) (repackaged from NDC 69452-234-20)\n                  NDC 76420-580-90 (Bottle of 90) (repackaged from NDC 69452-234-20)\n                  NDC 76420-580-10 (Bottle of 100) (relabeled from NDC 69452-234-20)\n                  \n                  Store at 20-25째C (68-77째F). [See USP Controlled Room Temperature]\n  \n                     \nProtect from excessive moisture\n \n                  Keep out of reach of children.\n                  Dispense in tight, light-resistant container as defined in USP/NF, accompanied by a Patient Insert.\n                  \n                     Relabeled and Repackaged by:\n                  \n                  Enovachem PHARMACEUTICALS\n                  Torrance, CA 90501",
    "adverseReactions_original": "Progesterone capsules should not be used in women with any of the following conditions:\n                  \n                     \n                        Progesterone capsules should not be used in patients with known hypersensitivity to its ingredients. Progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts.\n                     \n                     Undiagnosed abnormal genital bleeding.\n                     Known, suspected, or history of breast cancer.\n                     Active deep vein thrombosis, pulmonary embolism or history of these conditions.\n                     Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions.\n                     Known liver dysfunction or disease.\n                     Known or suspected pregnancy."
}